Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine > News > Lynch syndrome patients show poor aspirin adherence
  • News

Lynch syndrome patients show poor aspirin adherence

  • 9 February 2024
  • Janet Fricker
Lynch syndrome patients show poor aspirin adherence
Total
0
Shares
0
0
0
0
0

Only around one third of people with Lynch syndrome, the most common form of hereditary colorectal cancer, report taking aspirin as chemopreventive therapy. The survey, abstract 19, presented at the 2024 ASCO Gastrointestinal Cancers Symposium, held January 18–20, in San Francisco, found poor uptake was associated with perceptions of inconvenience, side effects and low preventive benefit.

“Even in this high-risk population, engagement in a chemoprevention choice that we know has been proven in a trial to be beneficial was not great,” says senior study author Michael Hall, Director of the Gastrointestinal Risk Assessment Program at Fox Chase Medical Center, Philadelphia, Pennsylvania. “We need to not only think about exciting new interventions, but about whether or not they are approachable for patients.”

People with Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), have an increased lifetime risk of developing colorectal cancer of up to 80%. The gene mutations MLH1, MSH2, MSH6, and PMS2 have been associated with Lynch syndrome. Regular screening with colonoscopy and polypectomy to identify precancerous cells has been the main strategy to detect early colorectal cancer in people with Lynch syndrome. However, interval colorectal cancers (detected in the interval between screenings) can still develop, and adjunctive therapies, such as aspirin and NSAIDs (non-steroidal anti-inflammatory drugs), have been recognised for chemopreventive benefits.

Results of the earlier CAPP2 study, involving 861 people with Lynch syndrome, published in The Lancet in 2011, demonstrated that receiving aspirin (600 mg a day), as opposed to placebo, for at least two years, could help to decrease the risk of developing colorectal cancer by around 60% in this high-risk population. However, despite such compelling data, rates of aspirin use for cancer prevention have remained low. “We had noted anecdotally that patients did not seem to be using aspirin as a chemo preventive,” explains Hall. Understanding why patients are not accessing preventive strategies has become of even greater consequence with the development of FSPVAX, a preventive peptide vaccine designed to recognise multiple mutated proteins frequently found in patients with Lynch syndrome.

In the current PREVENTLynch study, investigators undertook a one-time ‘e-survey’, asking people in the FOX Chase risk registry about perceptions of chemoprevention agents including aspirin, and colonoscopy. The survey was further disseminated by posting it online and promoting it to people diagnosed with Lynch syndrome outside the US through two advocacy websites. Perceived inconvenience, side effects, reassurance, and the likelihood of recommending available and emerging cancer prevention modalities were measured on a 9-point scale (where low=1). Demographics and personal and familial history of cancer were also collected.

The survey was completed by 296 people with Lynch syndrome, with a median age of 53 years, of whom 56.4% had a personal history of cancer. The findings show that colonoscopy was performed every year in 70.7% of respondents from the US and 68.2% from outside the US, and every two to three years in 27.7% of respondents from the US and 27.2% from outside the US. In contrast, aspirin was taken by only 34.1% of the US respondents and 36.4% of the non-US respondents.

Differences between users of chemoprevention (including aspirin and NSAIDs) and non-users included: perceived greater convenience (mean score 1.32 vs 1.90 respectively, P=0.02); lower concern for side effects (2.30 vs 3.61, P=0.0008); and higher perceived preventive reassurance from chemopreventive use (5.68 vs 3.93, P<0.0001). Interestingly, the difference for the perception of convenience was not very different between people who took it and people who did not.

Investigators identified no significant differences among people who did and did not take aspirin based on age (P=0.24); gender (P=0.16); race (P=0.48); whether they had a personal history of cancer (P=0.06); and underlying Lynch syndrome genetic subtypes (MLH1, MSH2, MSH6, PMS2; P=0.49).

In comparison to colonoscopy, FSPVAX was viewed as more convenient, but with higher side effects, and lower perceptions of efficacy (all P<0.001). In comparison to chemoprevention, FSPVAX was viewed as less convenient, with greater concerns about side effects, but as having higher potential preventive efficacy (all P<0.001).

While US patients viewed aspirin as more convenient than non-US patients, and with a lower risk of side effects (P=0.007), they were no more likely to recommend chemoprevention. US patients also perceived more side effects risk from the FSPVAX than non-US patients (P=0.003).

“Patient perceptions of CP [chemo prevention] convenience, side effects and preventive benefits predicted CP uptake whereas factors such as age, sex, geographical location, gene affected and personal history of malignancy did not. This suggests a critical need for education addressing negative perceptions of CP among LS patients to improve CP uptake,” conclude the authors.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • adherence
  • Chemoprevention
  • colonoscopy
  • education
  • FSPVAX
  • hereditary non-polyposis colorectal cancer
  • lynch syndrome
  • MLH1
  • MSH2
  • MSH6
  • patient preferences
  • PMS2
  • prevention
  • preventive vaccine
  • shared decision making
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Articles
  • Delivery of Care

Hero? Survivor? Using the right words matters, but it’s not always straightforward

  • 9 February 2024
  • Victoria Forster
View Post
Next Article
  • Articles
  • Policy

Not just a climate issue: cutting cancer rates through cleaner cooking fuels in Africa

  • 9 February 2024
  • Esther Nakkazi
View Post
You May Also Like
View Post
  • Articles
  • Medicine
  • News

Common Diabetes Medication Could Protect Heart Health During Cancer Treatment

  • Janet Fricker
  • 30 May 2025
View Post
  • Articles
  • News

CancerWorld issue #103 (May, 2025)

  • Yeva Margaryan
  • 11 May 2025
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Janet Fricker
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Janet Fricker
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Janet Fricker
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Common Diabetes Medication Could Protect Heart Health During Cancer Treatment
    • 30 May 2025
  • CancerWorld issue #103 (May, 2025)
    • 11 May 2025
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
Article
  • Albinism And Skin Cancer In Africa: Tackling The Prevention Needs Of A Stigmatised Population
    • 30 May 2025
  • Common Diabetes Medication Could Protect Heart Health During Cancer Treatment
    • 30 May 2025
  • Why Patient-Reported Outcomes are Rarely Used in Trials, and How We Change That
    • 27 May 2025
Social

Would you follow us ?

Contents
  • A Promise Kept: How Samvel Danielyan Lifted Pediatric Cancer Survival from Zero to 70%
    • 25 May 2025
  • Together, She Changed Everything: Martine Piccart ’s Fight Against Breast Cancer
    • 20 May 2025
  • Adrian Gottschalk: Making a Difference for His Fellow Human Beings
    • 10 May 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.